Osmotica Pharmaceutical Corp and Upstate Pharma, LLC, a subsidiary of
UCB, Inc., Announce the Availability of Venlafaxine Extended-Release
Tablets
WILMINGTON, N.C. (Business Wire EON/PRWEB ) October 9, 2008 --
Osmotica Pharmaceutical Corp. is announcing that Venlafaxine
Extended-Release Tablets, 37.5 mg, 75 mg, 150 mg, and 225 mg, which was
approved by the U.S. Food and Drug Administration in May, is now
commercially available through its marketing partner, Upstate Pharma,
LLC, a subsidiary of UCB, Inc. Shipments of the product to wholesalers
and other commercial outlets began September 30, 2008 and promotion of
the product will commence later in the month. Forrest Waldon, CEO of
Osmotica Pharmaceutical stated, “We are
excited about the launch of this innovative product and look forward to
a successful commercial relationship.”
Important Safety Information
There is an increased risk of suicidal thinking and behavior in
children, adolescents and young adults taking antidepressants for major
depressive disorder (MDD) and other psychiatric disorders. Venlafaxine
HCl Extended Release Tablets are not approved for use in pediatric
patients.
People taking Monoamine oxidase inhibitors (MAOIs) should not take
Venlafaxine HCl Extended-release Tablets. Venlafaxine HCl
Extended-release Tablets may raise blood pressure in some patients. Your
blood pressure should be controlled before starting treatment and should
be monitored regularly. Other side effects reported in at least 10% of
patients in clinical studies and at a rate at least twice that of the
placebo group include: abnormal ejaculation (men), anorexia, dizziness,
dry mouth, impotence, insomnia, nausea, nervousness, somnolence,
sweating, and weakness. Ask your doctor if Venlafaxine HCl
Extended-release Tablets are right for you.
About Osmotica Pharmaceutical
Osmotica Pharmaceutical is part of a multi-national group of
pharmaceutical companies (the “Osmotica Group”)
specializing in neurology based drug therapies and delivery
technologies. The Osmotica Group has a portfolio of products in various
stages of development focused in the treatment of Parkinson's disease.
In addition, the Osmotica Group utilizes its well established drug
delivery technologies (including its Osmodex®
technologies) and its expertise to develop drug candidates for partner
companies. The Osmotica Group has a track record of successfully
developing and commercializing products in the US, Europe and other
countries around the world.
The Osmotica Group’s principal operations are
located in the United States and Argentina and its products are
manufactured in the U.S., Argentina and Spain.
For more information on the Company, please visit Osmotica’s
website at www.osmotica.com.
This press release is directed to residents of the United States.
See the original story at: http://eon.businesswire.com/releases/osmotica_pharmaceutical/release_tablets/prweb1450614.htm
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/SW5zZS1NYWduLUNvdXAtQ291cC1JbnNlLVNpbmctWmVybw==
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
